Spoken Alpha
Profusa, Inc.
Profusa designs and develops a biosensor platform called Lumee that measures real-time biochemistry through subcutaneously injected hydrogel sensors paired with wearable optical readers.
Profusa, Inc is a Healthcare company operating in Medical Devices with a $533,134 market cap.
Most recent reported earnings: Q2 FY2026 (Aug 12, 2026).
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-06-21.
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add PFSA, reply to your welcome email and we'll prioritize it.
History
Spoken Alpha tracks PFSA's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 80% of the time
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for PFSA.
$ curl https://api.spokenalpha.com/v1/companies/PFSAFAQ
Spoken Alpha indexes PFSA's earnings call transcripts at https://spokenalpha.com/companies/PFSA. Each call links to attributed speakers and parsed analyst Q&A. Profusa, Inc.'s own investor relations page is at https://investors.profusa.com/.
Profusa, Inc. (PFSA) operates in the Healthcare sector (Medical Devices industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-12 | — | — | — | — | — | — | EODHD |
| Q1 FY2026 | 2026-03-30 | $-2.05 | — | — | $0 | — | — | EODHD |
| Q4 FY2025 | 2025-12-30 | $-6.95 | — | — | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-18 | $-0.70 | $0.00 | — | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-21 | $-0.42 | — | — | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-06-26 | $-0.48 | — | — | $0 | — | — | EODHD |
| Q4 FY2024 | 2024-12-30 | $-96.73 | — | — | $0 | — | — | EODHD |
| Q3 FY2024 | 2024-09-29 | $1.15 | — | — | $75.0K | — | — | EODHD |
| Q2 FY2024 | 2024-06-29 | $-5.74 | — | — | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-03-30 | $-10.22 | — | — | $0 | — | — | EODHD |
| Q4 FY2023 | 2023-12-30 | $2.94 | — | — | — | — | — | EODHD |
| Q3 FY2023 | 2023-09-29 | $-4.47 | — | — | — | — | — | EODHD |
| Q2 FY2023 | 2023-06-29 | $10.36 | — | — | — | — | — | EODHD |
| Q1 FY2023 | 2023-03-30 | $1.51 | — | — | — | — | — | EODHD |
| Q4 FY2022 | 2022-12-30 | $1.50 | — | — | — | — | — | EODHD |
| Q3 FY2022 | 2022-09-29 | $5.47 | — | — | — | — | — | EODHD |
| Q2 FY2022 | 2022-06-29 | $3.76 | — | — | — | — | — | EODHD |
| Q1 FY2022 | 2022-03-30 | $11.51 | — | — | — | — | — | EODHD |
Source: EODHD. PFSA reported actuals as published; sparse fields render as —.
When a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.20 | $1.84 | +19.5% | -2.8% | -4.3% |
| Q4 FY2026 | $2.80 | $2.09 | +34.0% | -0.4% | +0.8% |
| Q3 FY2026 | $2.36 | $1.92 | +22.8% | -0.4% | -0.1% |
| Q2 FY2026 | $2.56 | $1.92 | +33.4% | +0.8% | +3.4% |
| Q1 FY2025 | $2.71 | $2.07 | +31.1% | -2.3% | -1.9% |
CFO since 2021 • 8/20 beats (40%) • guidance suspended Q3 FY2026
| Q4 FY2025 |
| $2.55 |
| $1.94 |
| +31.7% |
| -6.6% |
| -5.7% |
| Q3 FY2025 | $2.91 | $2.19 | +33.1% | -6.7% | -6.7% |
| Q2 FY2025 | $2.53 | $2.04 | +24.0% | -2.3% | -3.9% |
| Q1 FY2024 | $2.69 | $2.22 | +21.2% | -5.6% | -2.9% |
| Q4 FY2024 | $2.43 | $1.96 | +24.2% | +1.1% | -1.6% |